8-KShareholder Matters

ABBOTT LABORATORIES 8-K Report, Shareholder Vote Results (Apr 29, 2013)

Filed April 29, 2013For Securities:ABT

Summary

This 8-K filing from Abbott Laboratories reports on the outcomes of its Annual Meeting of Shareholders held on April 26, 2013. The primary focus is on the voting results for various proposals, including the election of directors, ratification of auditors, executive compensation, and several shareholder proposals. Notably, all of Abbott's director nominees were elected with strong support, and the appointment of Deloitte & Touche LLP as the company's independent auditor was overwhelmingly ratified. Shareholders also provided an advisory vote to approve the compensation of named executive officers. However, a significant number of shareholder proposals, covering areas such as genetically engineered ingredients, lobbying disclosure, board independence, executive share retention, exclusion of compliance costs from incentive compensation, and change of control equity vesting, were all rejected by a substantial margin.

Key Highlights

  • 1All director nominees for Abbott Laboratories were successfully elected at the Annual Meeting of Shareholders.
  • 2Shareholders overwhelmingly ratified the appointment of Deloitte & Touche LLP as the company's independent auditor.
  • 3An advisory vote to approve the compensation of Abbott's named executive officers received 84.52% of the votes cast in favor.
  • 4Shareholder proposals concerning genetically engineered ingredients in nutritional products, lobbying disclosures, and independent board chair were all rejected with low support.
  • 5Shareholder proposals related to executive share retention policies, executive compensation metrics excluding compliance costs, and accelerated equity vesting upon change of control were also rejected by a significant majority.
  • 6The filing provides detailed voting results, including votes for, against, abstained, and broker non-votes for each matter.
  • 7Thomas C. Freyman, Executive Vice President, Finance and Chief Financial Officer, signed the report.

Frequently Asked Questions

The Annual Shareholder Meeting resulted in the election of all director nominees and the ratification of Deloitte & Touche LLP as auditors. Shareholders also approved executive compensation on an advisory basis. However, several shareholder proposals covering various governance and product-related matters were rejected.

Yes, shareholders provided an advisory vote to approve the compensation of Abbott's named executive officers. Approximately 84.52% of the votes cast were in favor of this proposal.

A majority of the shareholder proposals were rejected. These included proposals requesting the removal of genetically engineered ingredients, adoption of lobbying disclosure policies, an independent board chairman, policies on executive share retention, exclusion of compliance costs from executive incentives, and a policy on accelerated equity vesting upon change of control.

Broker non-votes indicate shares held by brokers that did not receive voting instructions from the beneficial owners for specific proposals where the broker does not have discretionary voting power. A significant number of broker non-votes (206,376,087) were recorded for the director elections and the executive compensation vote, which can impact the perceived level of support if all outstanding shares were factored in.